Figure 2.

Adjunct therapy with C₄.T₄ in combination with anti-TB drugs restricted the survival of Mtb. (A) BMDMs were infected with H37Rv for 4 h and treated with CLEC4E (SYK-piceatannol) and TLR4 (CLI-095) signaling inhibitors for 1 h, prior to C₄.T₄ stimulation for 48 h, then (B,C) infected cells were treated with (B) rifampicin (0.5 µg/ml) or (C) isoniazid (2.5 µg/ml) along with C₄.T₄ for 48 h. The infected macrophages were lysed and CFUs were enumerated after 21 d. UT, untreated and Mtb infected; C₄, CLEC4E agonist (TDB); T₄, TLR4 agonist (ultra-pure LPS); ns, non-significant; RIF, rifampicin; INH, isoniazid. Data present as the mean ± SEM of 4 wells and are from 3 independent experiments. Data were analyzed by one-way ANOVA repeated measure *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.